Abstract 529P
Background
Patients (pts) with colorectal cancer (CRC) who experience metastatic spread to many distant organs have been shown to have poorer survival rates. It is still unknown if the location of distant metastases impacts survival outcomes. The aim of this real-world substudy was to assess the survival differences by metastatic patterns in pts receiving sequential treatment with regorafenib (R) and trifluridine/tipiracil (T) and vice versa. The endpoints were median overall survival (mOS) and median progression-free survival (mPFS).
Methods
Clinical data on pts diagnosed with metastatic CRC who were treated with R and T from 2012 to 2023 have been collected retrospectively at 17 Italian cancer centers.
Results
1156 pts who were treated with sequential R and T (T/R, n=261; R/T, n=155) or T (n=427) or R (n=313) alone, were retrospectively enrolled. In this subgroups study, we focused on pts who received T/R or R/T sequences. We observed a statistically significant longer mOS in pts who were treated with R/T vs the reverse sequence: 17.6 vs 9.8 months (HR=0,55; p=0,0449) in pts with liver metastases only (n=47) and 16 vs 12 months (HR=0,61; p=0,0018) in pts with liver + other metastases (n=173), respectively. A similar result in mOS, albeit non statistically significant, was shown in pts with other than liver metastases (n=112) in R/T vs T/R group [16,6 vs 14,7 months (HR=0,85; p=0,4255)]. In terms of mPFS, we observed a statistically significant better outcome in R/T than T/R group: 11,3 vs 7.6 months (HR=0,53; p=0,0272) in pts with liver metastases only (n=55); 11,1 vs 8,5 months (HR=0,67; p=0,0090) in pts with liver + other metastases (n=195) and 11,5 vs 8,9 months (HR=0,57; p=0,0018) in pts with other than liver metastases (n=136), respectively.
Conclusions
According to this real-world subanalysis, the R/T sequence could improve survival outcomes in third-line treatment and beyond in CRC pts with any metastatic pattern. However, treatment choices should also take into account the patient's characteristics, including gender and ECOG PS. To validate our results, further prospective research is needed.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
533P - First-line treatment in older patients with metastatic colorectal cancer: A large real-world study
Presenter: debora basile
Session: Poster session 15
534P - Second-line treatment in older patients with metastatic colorectal cancer: The ELECTRA study
Presenter: Alessia Cordua
Session: Poster session 15
535P - Safety and efficacy of first-line immune checkpoint inhibitors in elderly colorectal cancer patients: An Italian real-world multicenter experience
Presenter: Alessandra Boccaccino
Session: Poster session 15
536P - A randomized phase II/III trial comparing hepatectomy followed by mFOLFOX6 with hepatectomy alone for liver metastasis from colorectal cancer: Long-term results of JCOG0603
Presenter: Yukihide Kanemitsu
Session: Poster session 15
537P - Stereotactic ablative radiotherapy combined with fruquintinib and tislelizumab in metastatic colorectal cancer: Updated findings from a single-arm, prospective phase II trial (RIFLE)
Presenter: Yajiie Chen
Session: Poster session 15
538P - Combined hepatectomy with complete cytoreduction (CCS) and hyperthermic intraperitoneal chemotherapy (HIPEC) vs. HIPEC alone for metastatic colorectal cancer: A systematic review and meta-analysis
Presenter: Gabriele Lech
Session: Poster session 15
540P - Early treatment discontinuation (ETD) in dMMR/MSI-H metastastic colorectal cancer (mCRC) treated with immune checkpoint inhibitors (ICIs)
Presenter: Julien Taieb
Session: Poster session 15
541P - Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Subgroup efficacy and expanded safety analyses from CheckMate 8HW
Presenter: Thierry André
Session: Poster session 15